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Abstract E⁄cient transcription from the human immunode¢-
ciency virus type 1 long terminal repeat (HIV-1 LTR) promoter
is dependent on the viral transactivator Tat. To generate a Tat-
independent proviral plasmid, we replaced the promoter in the
HIV-1 LTR with the immediate early promoter of cytomegalo-
virus. Transfection of this plasmid yielded Tat-independent pro-
duction of infectious HIV-1. Tat-independent expression was
lost, however, when the major 5P splice site in the HIV-1 ge-
nome was mutated and no HIV-1-speci¢c RNA or protein was
detected. This defect was restored when a Tat expression plas-
mid was cotransfected. Our results support recent reports indi-
cating an in£uence of the recognition of splice sites on e⁄cient
transcriptional elongation.
, 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Cellular homeostasis requires balanced gene expression
which is partly regulated at the level of mRNA transcription.
Transcriptional control occurs at the level of initiation, but
also at the level of elongation as shown by the isolation of
positive and negative elongation factors [1]. An early example
for transcriptional control by regulating elongation has been
human immunode¢ciency virus (HIV) type 1. After infection
of a susceptible cell, the RNA genome of HIV-1 is reverse-
transcribed into DNA and subsequently integrated into the
cellular genome. The integrated provirus is transcribed by
cellular RNA polymerase II (pol II), yielding a single primary
transcript of approximately 9 kb [2]. At early times of infec-
tion, however, very few full-length transcripts are synthesized
due to non-processive pol II complexes initiating from the
viral promoter [3]. These transcripts are completely spliced
leading to translation of the viral transactivator Tat [4]. The
Tat protein binds to a unique RNA structure termed TAR
(transactivation response element) at the 5P end of all HIV-1
transcripts [5]. This complex then recruits cyclin T1 and the
associated kinase CDK9 which are part of the cellular elon-
gation factor pTEFb [6]. Subsequently, CDK9 phosphorylates
the C-terminal domain (CTD) of RNA pol II, thus generating
highly processive elongation complexes and stimulating HIV-1
transcription by a factor of up to 100 [7].
The molecular mechanism of Tat function has been eluci-
dated in recent years, but it is still largely unknown why
initiation at the HIV-1 long terminal repeat (LTR) promoter
gives rise to non-processive RNA pol II complexes. Clearly,
HIV-1 gene products can be produced independent of Tat
when placed under control of a heterologous, Tat-independent
promoter, e.g. the immediate early promoter of cytomegalo-
virus (CMV). To generate a Tat-independent proviral plas-
mid, we placed the HIV-1 transcription unit under control
of the CMV promoter. Here, we show that the CMV-driven
proviral plasmid leads to e⁄cient Tat-independent production
of infectious HIV-1. However, Tat-independent gene expres-
sion was lost when a mutation was introduced into the major
5P splice site (5Pss) of HIV-1. This result supports other re-
ports indicating that recognition of 5Pss may regulate tran-
scriptional elongation.
2. Materials and methods
2.1. Plasmids
To replace the U3 region in the 5P LTR of the proviral HIV-1
plasmid pNL4-3 [8] by the CMV promoter, an overlap polymerase
chain reaction (PCR) was performed. The CMV promoter was am-
pli¢ed from pC1-green £uorescent protein (GFP) (Clontech) using
primers 5PCMV+ (GTG AAC CGG GTC TCT CTG GTT AGA
CCA GAT CTG AGC C), introducing a unique Bst1107I site and
3PCMV+ overlap (GGT CTA ACC AGA GAG ACC CGG TTC
ACT AAA CCA GCT CTG), containing 10 nucleotides at the
5P end which are complementary to the transcription start site of
NL4-3 (nt 451). The HIV-1-speci¢c sequence was ampli¢ed from
pNL4-3 using primers 5PCMV overlap (CGG AGT ATA CTA
GTT ATT AAT AGT AAT CAA TTA CG) and RW MAR2
(CCC TTT CTT TGT TAT A). Both products were re-ampli¢ed
with primers 5PCMV+ and RW MAR2. The product was cloned
into a derivative of pNL4-3 containing a silent NgoMI site immedi-
ately adjacent to the major 5Pss [9]. The PCR-derived region in the
resulting plasmid, termed pNLC4-3, was con¢rmed by sequence anal-
ysis. To construct a tat/rev-negative derivative, the EcoRI/NheI frag-
ment from a tat/rev-negative subgenomic HIV-1 plasmid (kindly pro-
vided by H. Schaal, Du«sseldorf, Germany) was transferred into
pNLC4-3 to yield pNLC4-3tr3. To introduce the M3 mutation into
the major 5Pss, the BssHII/EcoRI fragment of pNL4-3tr3M3 [9] was
transferred into pNLC4-3tr3.
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2.2. Cells and transfection
HeLa P4 and 293T cells were maintained in Dulbecco’s modi¢ed
Eagle’s medium with 10% heat-inactivated fetal calf serum, 100 U/ml
penicillin, 100 Wg/ml streptomycin and 2 mM glutamine. Sup-T1 cells
were cultivated in RPMI 1640 medium with the same additives. For
transient transfection, 5U105 HeLa P4 or 293T cells were seeded and
transfected with 10 Wg of the respective plasmid and 1 Wg of a reporter
construct encoding GFP using the modi¢ed calcium phosphate copre-
cipitation technique [10]. To assess transfection e⁄ciency, coverslips
were ¢xed for 10 min with 4% paraformaldehyde in phosphate-bu¡-
ered saline and £uorescence-positive cells were counted. For trans-
fection of Sup-T1 cells, 5U106 cells were electroporated with a Bio-
Rad gene pulser in the presence of 15 Wg DNA using 250 V and 960
WF. Cells electroporated with a GFP expression plasmid served as
transfection controls and were analyzed by £uorescence-associated
cell sorting to determine transfection e⁄ciency.
2.3. Western blot analysis
Cells were harvested at 60 h post transfection. Cell lysates were
normalized for transfection e⁄ciency and analyzed by sodium dodecyl
sulfate^polyacrylamide gel electrophoresis and immunoblotting
using antisera against HIV-1 capsid (CA; 1:10 000), Env (1:5000,
kindly provided by V. Bosch, Heidelberg, Germany) or Nef pro-
teins (1:5000) and an antibody directed against Erk2 as a loading
control (Santa Cruz, Santa Cruz, CA, USA) and peroxidase-conju-
gated secondary antibody (Dianova, Hamburg, Germany). Enhanced
chemiluminescence (Amersham) was used for detection according to
the manufacturer’s protocol. Blots were exposed to Kodak Biomax
¢lms.
2.4. RNA preparation and analysis
Preparation of total RNA, gel electrophoresis, blotting and detec-
tion with a radiolabeled probe were performed as described [11]. Blots
were washed, sealed and exposed to X-ray ¢lms (Kodak X-omat-AR)
or quanti¢ed by phosphoimage analysis (Bio-Rad).
2.5. Virus titration
Filtered supernatants from transfected 293T cells were analyzed for
HIV-1 CA antigen by enzyme-linked immunosorbent assay and virus
inocula corresponding to 0.1^100 ng CA antigen were used to infect
HeLa P4 cells. After 60 h, cells were ¢xed and HIV-1-infected cells
were detected by immunostaining with a monoclonal antibody against
CA and a L-galactosidase-conjugated goat anti-mouse secondary anti-
body.
Fig. 1. CMV-driven HIV-1 expression. A: Schematic depiction of the HIV-1 proviral plasmid pNL4-3 (middle); the wild-type LTR region
(pNL4-3, top) and the CMV-containing LTR region (pNLC4-3, bottom) are expanded. The positions of the gag, env, rev, and tat genes are in-
dicated. The transcriptional start site (+1), the major 5Pss and the region detected by the probe used for Northern blotting are shown. B: Im-
munoblot analysis of HeLa P4 cells mock-transfected (lane 1) or transfected with 10 Wg pNLC4-3 (lane 2) or pNL4-3 (lane 3). Equal loading
was checked by staining the blot with Ponceau S. HIV-1-speci¢c proteins were detected with antiserum against CA (top), gp120 (middle) or
Nef (bottom). Relevant HIV-speci¢c proteins are identi¢ed on the right. C: Immunoblot analysis of Sup-T1 cells mock-transfected (lane 1) or
transfected with 15 Wg of pNL4-3 (lane 2) or pNLC4-3 (lane 3). Analysis was as in Fig. 2B, detection with antibodies against Erk2 is included
as a loading control.
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3. Results
3.1. A CMV-driven HIV-1 proviral plasmid yields production
of infectious HIV-1
E⁄cient transcription from the HIV-1 5P LTR promoter is
completely dependent on the viral transactivator protein Tat.
In order to generate a Tat-independent proviral plasmid, we
replaced the U3 region in the HIV-1 5P LTR, which contains
the viral promoter and enhancer, with the immediate early
promoter of CMV. In the resulting plasmid pNLC4-3, the
transcription start site of the HIV-1 genome is placed directly
adjacent to the CMV promoter such that the resulting tran-
script is identical to the HIV-1 genomic RNA (Fig. 1A).
Transfection of pNLC4-3 is expected to yield infectious virus,
since the U3 region will be regenerated upon reverse tran-
scription in the newly infected cell [2] and the integrated pro-
viral DNA should be identical with that obtained after wild-
type HIV-1 infection.
Immunoblot analysis of HeLa P4 cells transfected with
pNL4-3 or pNLC4-3 showed a very similar pattern of protein
expression in both cases (Fig. 1B). Western blots stained with
antisera detecting the HIV-1 CA protein revealed equal ex-
pression levels for CA, the Gag precursor protein Pr55 and
intermediate cleavage products in pNLC4-3- and pNL4-3-
transfected cells, respectively (Fig. 1B, upper panel, lanes 2
and 3). Analysis with antisera against the viral envelope pro-
teins (middle panel) and the HIV-1 accessory protein Nef
(lower panel) showed equal expression for the glycoproteins
gp160 and gp120 and for the Nef protein as well. To test the
relative infectivity of particles produced from pNLC4-3-trans-
Fig. 2. Analysis of the Tat and Rev dependence of HIV-1 gene expression from pNLC4-3 and a derivative with a mutation in the major 5Pss.
A: The sequence of the HIV-1 major 5Pss is shown in the middle and the sequence of the M3 mutant at the bottom. Altered nucleotides are in
bold. The complementary region of U1 snRNA is shown in the top line and hydrogen bonds with the 5Pss are depicted as vertical lines. The
slash indicates the exon/intron junction. B: Immunoblot analysis of HeLa P4 cells mock-transfected (lane 1) or transfected with plasmids
pNLC4-3 (lane 2), pNLC4-3tr3 (lanes 3^6) or pNLC4-3tr3M3 (lanes 7^10) carrying the M3 mutation in the 5Pss. Expression vectors for HIV-1
Tat and Rev were cotransfected as indicated above each lane. Equal loading was checked by staining the blot with Ponceau S. HIV-1 Gag pro-
teins were detected with antiserum against CA. C: Northern blot analysis of cells derived from the same transfection experiment as in B. HIV-
1-speci¢c RNA was detected with a labeled probe against the 3P LTR (indicated in Fig. 1A). The blot was reprobed for GAPDH as loading
control (lower panel). Lanes are as in B.
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fected cells, 293T cells were transfected with pNL4-3 or
pNLC4-3 in triplicate and ¢ltered media were tested for
HIV-1 antigen release and for infectious titer on HeLa P4
cells. Media from pNLC4-3-transfected cells contained
slightly higher antigen levels than media from pNL4-3-trans-
fected cells (821 ng versus 610 ng CA/ml), while their infec-
tious titer was approximately twofold lower (55 infectious
units versus 132 infectious units per ng CA). To assess the
expression levels in a HIV-infectable T cell line, Sup-T1 cells
were transfected with pNL4-3 and pNLC4-3, respectively, and
viral protein expression was analyzed by immunoblot (Fig.
2C). Similar to the result observed for HeLa P4 cells, expres-
sion levels of the Gag, Env and Nef proteins were approxi-
mately equal in both cases. Thus, transfection of the CMV-
driven HIV-1 proviral plasmid yielded e⁄cient release of in-
fectious HIV-1 particles and produced an expression pattern
virtually indistinguishable from wild-type virus.
3.2. HIV-1 expression from pNLC4-3 is Tat-independent
Following transfection of pNLC4-3 endogenous Tat is pro-
duced. To determine whether transcription from pNLC4-3 is
Tat-independent, we constructed plasmids pNL4-3tr3 and
pNLC4-3tr3, which carry mutations in the start codons of
the rev and tat genes. Accordingly, expression from the
LTR-driven proviral clone pNL4-3tr3 was completely depen-
dent on cotransfection of expression vectors for Tat and Rev
(data not shown). In the case of pNLC4-3tr3, on the other
hand, only cotransfection of a Rev but not of a Tat expression
plasmid is required. In the absence of Rev, only trace amounts
of Pr55 were detected (Fig. 2B, lane 3), while cotransfection of
a Rev expression plasmid largely restored production of HIV-
1-speci¢c proteins (Fig. 2B, lane 4). Cotransfection of a Tat
expression vector in the absence of Rev had no e¡ect (Fig. 2B,
lane 5), while cotransfection of Rev and Tat expression plas-
mids stimulated Gag expression twofold compared to cotrans-
fecting only a Rev expression vector (Fig. 2B, lane 6). A
similar picture was seen when total RNA from the same trans-
fection experiment was analyzed by Northern blot using a
probe speci¢c for the HIV-1 3P LTR (Fig. 2C). This probe
recognizes all three classes of HIV-1-speci¢c RNA. Following
transfection of pNLC4-3, the unspliced genomic RNA (ca.
9 kb), partially spliced RNAs (ca. 4 kb), and completely
spliced RNAs (ca. 2 kb) were observed (Fig. 2C, lane 2).
This result was very similar to that observed for wild-type
pNL4-3-transfected cells (data not shown). In the absence of
Rev, the amount of multiply spliced RNA was strongly in-
creased at the expense of unspliced and singly spliced RNA
(Fig. 2B, lanes 3 and 5). Importantly, however, e⁄cient RNA
production was seen in all cases, independent of the presence
or absence of Tat (Fig. 2B, lanes 3^6). Again, cotransfection
of a Tat expression plasmid stimulated RNA production ap-
proximately twofold as determined by phosphoimage analysis
of the respective products normalized for GAPDH levels.
Thus, transcription of HIV-1 genomic RNA from pNLC4-3
does not require Tat but is slightly stimulated by Tat.
3.3. Mutation of the major 5Pss of HIV-1 renders pNLC4-3
Tat-dependent
In another study we had shown that mutating the major
5Pss in the proviral plasmid pNL4-3 led to partially Rev-in-
dependent expression of the HIV-1 structural proteins [9]. The
major 5Pss located upstream of the gag open reading frame
(Fig. 1A) was inactivated by three point mutations, reducing
the number of hydrogen bonds between the 5Pss and U1
snRNA (Fig. 2A). In addition, the GU dinucleotide as well
as a cryptic 5Pss four nucleotides downstream were eliminated.
Transfection of the proviral plasmid pNL4-3tr3M3 led to pro-
duction of genomic RNA without further splicing and to par-
tially Rev-independent Gag expression [9]. A very di¡erent
picture was observed when the same M3 mutation in the
major 5Pss was analyzed in the context of the CMV-driven
plasmid pNLC4-3tr3. Virtually no Gag expression and no
HIV-1-speci¢c RNA was observed following transfection of
pNLC4-3tr3M3, both in the absence (Fig. 2B,C, lanes 7) and
in the presence (Fig. 2B,C, lanes 8) of Rev. Cotransfection of
a Tat expression plasmid together with pNLC4-3tr3M3 and a
Rev expression plasmid, on the other hand, restored produc-
tion of HIV-1 genomic RNA (Fig. 2C, lane 10) and of viral
Gag proteins (Fig. 2B, lane 10). Furthermore, cotransfection
of a Tat expression vector partially restored genomic RNA
and Gag protein expression even in the absence of Rev (Fig.
2B,C, lanes 9).
4. Discussion
In this report, we have shown that infectious HIV-1 can be
produced from a proviral plasmid containing a heterologous
promoter independent of Tat only when the major 5Pss in the
5P untranslated region of the genome is retained. Mutation of
this 5Pss renders transcription Tat-dependent with no speci¢c
RNA detected in the absence of Tat. Thus, in this context,
transcription from the CMV promoter requires either a func-
tional 5Pss or the stimulatory e¡ects of Tat for elongation.
This result raises the question how a signal for RNA process-
ing may in£uence transcriptional elongation. It is generally
accepted that splicing occurs cotranscriptionally [12,13], and
splicing factors associate with the nascent transcript immedi-
ately after the RNA emerges from the polymerase [14]. In the
presence of Tat, cyclin T1 and CDK9 co-assemble with Tat
on the TAR region of the nascent RNA, thus facilitating
hyperphosphorylation of the pol II CTD. The CTD of cyclin
T1 also binds the protein Tat-SF1 [15], which is believed to be
a general elongation factor. Interestingly, Tat-SF1 shows ho-
mologies to the yeast splicing factor CUS2, and Fong and
Zhou showed that Tat-SF1 links the splicing machinery to
transcription via cyclin T1 [16]. One may speculate, therefore,
that Tat-SF1 may be recruited to the major 5Pss of HIV-1
leading to the further recruitment of cyclin T1 and CDK9
to TAR and to Tat-independent expression of HIV-1 from
the CMV promoter (Fig. 3A). If a Tat expression vector is
cotransfected, elongation is further stimulated by a factor of
2 due to the direct e¡ects of Tat (Fig. 3B). If the major 5Pss is
mutated, however, Tat-SF1 or other factors cannot be re-
cruited and elongation-competent complexes are not formed
(Fig. 3C). In the presence of Tat, on the other hand, co-as-
sembly of Tat, cyclin T1 and CDK9 on the TAR region and
thus elongation is restored (Fig. 3D).
Tat and the major 5Pss appear to perform redundant func-
tions in the CMV-driven HIV-1 proviral plasmid, leading to
the question whether expression from the CMV promoter
needs associated 5Pss also in other cases and why the HIV-1
promoter is Tat-dependent even when a functional 5Pss is
present. The group of Proudfoot observed that a mutation
of a 5Pss close to the CMV promoter in a synthetic minigene
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construct inhibited transcription [17], indicating that our ob-
servation may not be restricted to the speci¢c case of HIV-1.
It is clear, however, that many CMV-driven genes can be ex-
pressed without an adjacent 5Pss and the molecular reason for
this di¡erence is currently not clear. An interesting parallel to
our system exists in the genome of CMV itself. The immediate
early protein 1, which is synthesized from the CMV immedi-
ate early promoter, is encoded by three exons with a func-
tional intron in the 5P untranslated region [18]. Conceivably,
splice sites may also be important for transcriptional elonga-
tion in this case and it would be interesting to test the e¡ects
of splice site mutations in this context. By analogy, all retro-
viruses contain a functional 5Pss in their 5P untranslated re-
gion and the presence of this 5Pss has been shown to be im-
portant for e⁄cient gene expression from retroviral vectors
[19]. The situation is di¡erent in the case of HIV-1, however,
where the viral LTR promoter requires Tat even when a func-
tional splice donor is present. This requirement must be de-
pendent on the promoter region since CMV-driven expression
is Tat-independent provided the 5Pss is present. Accordingly,
di¡erences in the promoter structure are likely to determine
the di¡erent requirements for e⁄cient elongation.
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